Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fibrin gel is a biodegradable, biocompatible biomaterial formed by the polymerization of fibrinogen and thrombin—key proteins in the blood clotting cascade. Upon mixing these components (often with calcium), thrombin cleaves fibrinogen to produce insoluble fibrin monomers that spontaneously assemble into a three-dimensional network or gel. This structure mimics natural blood clots and serves as a scaffold for cell attachment, migration, and proliferation during tissue repair. Fibrin gels are widely used clinically as hemostatic agents (fibrin glue/sealant) to control bleeding during surgery when conventional methods are insufficient or impractical. They also serve as scaffolds in tissue engineering for wound healing, cartilage repair, cardiovascular applications, ophthalmic procedures (e.g., corneal transplantation), nerve reattachment, skin graft adhesion, and regenerative medicine research. Fibrin gels degrade naturally via plasmin-mediated fibrinolysis and exhibit minimal inflammation or foreign body reaction[1][2][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fibrin gel.